title: The importance of proper bioinformatics analysis and clinical interpretation of tumor genomic profiling: a case study of undifferentiated sarcoma and a constitutional pathogenic BRCA2 mutation and an MLH1 variant of uncertain significance.
abstract: Next-generation sequencing (NGS) technology is increasingly utilized to identify therapeutic targets for patients with malignancy. This technology also has the capability to reveal the presence of constitutional genetic alterations, which may have significant implications for patients and their family members. Here we present the case of a 23 year old Caucasian patient with recurrent undifferentiated sarcoma who had NGS-based tumor analysis using an assay which simultaneously analyzed the entire coding sequence of 236 cancer-related genes (3769 exons) plus 47 introns from 19 genes often rearranged or altered in cancer. Pathogenic alterations were reported in tumor as the predicted protein alterations, BRCA2 "R645fs*15″ and MLH1 "E694*". Because constitutional BRCA2 and MLH1 gene mutations are associated with Hereditary Breast Ovarian Cancer Syndrome (HBOCS) and Lynch syndrome respectively, sequence analysis of DNA isolated from peripheral blood was performed. The presence of the alterations, BRCA2 c.1929delG and MLH1 c.2080G>T, corresponding to the previously reported predicted protein alterations, were confirmed by Sanger sequencing in the constitutional DNA. An additional DNA finding was reported in this analysis, MLH1 c.2081A>C at the neighboring nucleotide. Further evaluation of the family revealed that all alterations were paternally inherited and the two MLH1 substitutions were in cis, more appropriately referred to as MLH1 c.2080_2081delGAinsTC, which is classified as a variant of uncertain significance. This case illustrates important considerations related to appropriate interpretation of NGS tumor results and follow-up of patients with potentially deleterious constitutional alterations.
authors.affiliation: Division of Hematology/Oncology/Bone Marrow Transplant, Nationwide Children's Hospital, 700 Children's Drive, Columbus, OH, USA, Elizabeth.varga@nationwidechildrens.org.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Varga
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Chao
authors.forename: Nicholas D
authors.initials: ND
authors.lastname: Yeager
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics / Q000473:pathology / Q000556:secondary / Q000628:therapy; D005260:Female; D005820:Genetic Testing; D023281:Genomics / Q000379:methods; D006801:Humans; D000070957:MutL Protein Homolog 1; D009687:Nuclear Proteins / Q000235:genetics*; D010375:Pedigree; D012509:Sarcoma / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D055815:Young Adult
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; C501486:MLH1 protein, human; D009687:Nuclear Proteins; D000070957:MutL Protein Homolog 1